<DOC>
	<DOC>NCT02634346</DOC>
	<brief_summary>This study will evaluate the efficacy of ALKS 3831 in adult subjects with acute exacerbation of schizophrenia.</brief_summary>
	<brief_title>A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Has a body mass index (BMI) of 18.0 40.0 kg/m^2 Meets criteria for the diagnosis of schizophrenia Resides in a stable living situation when not hospitalized Is willing and able to provide governmentissued identification Additional criteria may apply Has had a psychiatric hospitalization for more than 30 days during the 90 days before screening Subject initiated first antipsychotic treatment within the past 12 months, or &lt;1 year has elapsed since the initial onset of activephase of schizophrenia symptoms Subject poses a current suicide risk Subject has a history of treatment resistance Subject has a history of poor or inadequate response to treatment with olanzapine Subject requires or has had electroconvulsive therapy (ECT) treatment in the 2month period prior to screening Subject has a diagnosis of moderate or severe alcohol or drug use disorder Subject has a positive urine drug screen for opioids, amphetamine/methamphetamine, phencyclidine, or cocaine at screening Additional criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Alkermes</keyword>
	<keyword>ALKS 3831</keyword>
	<keyword>Samidorphan</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Acute Exacerbation of Schizophrenia</keyword>
</DOC>